Referred to the House Committee on Energy and Commerce.
This bill, the Special Diabetes Program Reauthorization Act of 2025, amends Section 330B(b)(2) of the Public Health Service Act to add an appropriation of $160,000,000 for each fiscal year 2026 through 2030 for Special Diabetes Programs for Type I diabetes, with the funds to remain available until expended. The statutory change also adjusts punctuation in existing subparagraphs; the substantive addition is the five‑year funding authorization.
Scope and adequacy of funding: liberals want larger or more comprehensive measures (e.g., insulin affordability, equity); conservatives view any recurring federal spending skeptically.
Relative to its intended legislative type, this bill is a narrowly focused statutory amendment that clearly and specifically authorizes multi-year funding for the Special Diabetes Program for Type I diabetes and integrates directly into the Public Health Service Act.
This bill, the Special Diabetes Program Reauthorization Act of 2025, amends Section 330B(b)(2) of the Public Health Service Act to add an appropriation of $160,000,000 for each fiscal year 2026 through 2030 for Special Diabetes Programs for Type I diabetes, with the funds to remain available until expended.
The statutory change also adjusts punctuation in existing subparagraphs; the substantive addition is the five‑year funding authorization.
The bill does not specify programmatic allocation details beyond the yearly appropriations or offsets for the new funding.
The bill is short, technocratic, and narrowly focused on extending funding for a disease program—features that favor enactment. Its principal risk is the fiscal impact (authorization of several hundred million dollars over five years) and potential procedural or prioritization obstacles in both chambers. Absent major controversy or competing legislative priorities, such reauthorizations often succeed, but lack of specified offsets and dependence on appropriations or execution details reduce certainty.
Relative to its intended legislative type, this bill is a narrowly focused statutory amendment that clearly and specifically authorizes multi-year funding for the Special Diabetes Program for Type I diabetes and integrates directly into the Public Health Service Act.
Scope and adequacy of funding: liberals want larger or more comprehensive measures (e.g., insulin affordability, equity); conservatives view any recurring federal spending skeptically.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and adequacy of funding: liberals want larger or more comprehensive measures (e.g., insulin affordability, equity); conservatives view any recurring federal spending skeptically.
A mainstream progressive would likely welcome the extension of dedicated federal funding for Type I diabetes research and programs as a positive public health investment.
They would emphasize the importance of sustained, predictable federal support for basic research, clinical trials, prevention and care access for people with Type I diabetes.
They may criticize the level of funding if they view it as insufficient relative to need or would note the bill does not address insulin affordability or broader diabetes disparities.
A mainstream centrist would generally view the bill favorably as a modest, targeted reauthorization to sustain an established disease‑focused program.
They would appreciate the continuity for research and programs while being mindful of fiscal discipline and oversight.
They would likely seek clarity on the program’s measurable outcomes, administrative use of funds, and whether this is funded within existing appropriations or increases net federal spending.
A mainstream conservative would weigh the public and political support for disease research against concerns about federal spending and scope.
Many conservatives generally support targeted medical research funding, especially for diseases like Type I diabetes, but would prefer limited durations, clear accountability, and assurances this does not expand federal programs unnecessarily.
Fiscal conservatives may request offsets or more restrictive language on fund use and duration.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
The bill is short, technocratic, and narrowly focused on extending funding for a disease program—features that favor enactment. Its principal risk is the fiscal impact (authorization of several hundred million dollars over five years) and potential procedural or prioritization obstacles in both chambers. Absent major controversy or competing legislative priorities, such reauthorizations often succeed, but lack of specified offsets and dependence on appropriations or execution details reduce certainty.
The bill has not accumulated any surfaced votes yet.
Scope and adequacy of funding: liberals want larger or more comprehensive measures (e.g., insulin affordability, equity); conservatives vie…
The bill is short, technocratic, and narrowly focused on extending funding for a disease program—features that favor enactment. Its princip…
Relative to its intended legislative type, this bill is a narrowly focused statutory amendment that clearly and specifically authorizes multi-year funding for the Special Diabetes Program for Type I diabetes and integra…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.